Financial Performance - Revenue for Q3 2024 was CNY 93,737,135.94, a decrease of 19.33% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 3,591,974.25, down 76.60% year-on-year[3]. - Net profit excluding non-recurring items was CNY 1,011,632.12, a decline of 90.50% compared to the previous year[3]. - Basic earnings per share were CNY 0.0332, reflecting a decrease of 76.59% year-on-year[3]. - Total operating revenue for the third quarter was CNY 330,879,995.68, a decrease of 2.35% compared to CNY 340,680,063.30 in the previous year[16]. - Total operating costs increased to CNY 303,707,035.89, up 9.79% from CNY 276,619,313.03 in the same period last year[16]. - The company reported a net profit of CNY 7,250,793.55, significantly up from CNY 1,674,693.95 in the previous year[16]. - Net profit for Q3 2024 was CNY 39,555,461.09, a decrease from CNY 66,554,829.52 in Q3 2023, representing a decline of approximately 40.7%[17]. - Operating profit for Q3 2024 was CNY 45,779,440.84, down from CNY 71,687,888.16 in the same period last year, indicating a decrease of about 36.2%[17]. - The total profit for Q3 2024 was CNY 42,917,141.46, a decrease from CNY 71,342,918.51 in Q3 2023, representing a decline of about 39.9%[17]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,464,668,161.73, a slight decrease of 0.36% from the end of the previous year[3]. - Non-current assets totaled CNY 820,808,350.76, an increase of 38.76% from CNY 591,179,352.17 at the beginning of the year[14]. - Total liabilities were CNY 127,190,433.73, a decrease of 8.48% from CNY 138,927,726.47[14]. - The total equity attributable to shareholders increased to CNY 1,336,620,591.67 from CNY 1,331,040,247.54, a growth of 0.35%[15]. Cash Flow - The company reported a net cash flow from operating activities of CNY 23,870,916.56, an increase of 26.72% year-to-date[3]. - Cash flow from operating activities for Q3 2024 was CNY 23,870,916.56, an increase from CNY 18,837,983.45 in Q3 2023, reflecting a growth of approximately 26.5%[18]. - Cash flow from investing activities for Q3 2024 was negative CNY 49,669,863.98, an improvement compared to negative CNY 581,719,915.74 in Q3 2023[19]. - The company reported a decrease in cash flow from financing activities, with a net cash outflow of CNY 31,487,820.72 in Q3 2024, compared to a net inflow of CNY 741,725,637.86 in Q3 2023[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,520[8]. - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 34.39% of shares, totaling 37,240,000 shares, with 27,840,000 shares pledged[8]. - The second-largest shareholder, Wenze Hong, holds 7.76% of shares, totaling 8,400,000 shares[8]. - The company has a total of 81,200,000 restricted shares, with 35,462,000 shares released during the period[11]. - The largest unrestricted shareholder, Wenze Hong, has 8,400,000 unrestricted shares[10]. - The company maintains a non-controlling relationship with Jinan Financial Investment Holding Group Co., Ltd., which holds 19.16% of shares[9]. Other Income and Expenses - Other income increased by 461.46% to CNY 13,859,141.13, primarily due to government subsidies[7]. - Investment income rose by 332.96% to CNY 7,250,793.55, attributed to increased returns from equity investments and short-term financial products[7]. - Research and development expenses were CNY 22,354,267.62, down 25.06% from CNY 29,830,782.38 year-over-year[16]. Market and Product Development - The company has no new shares issued or additional restricted shares during the reporting period[11]. - The company has no plans for new product launches or technological developments mentioned in the report[11]. - There are no significant market expansion or acquisition strategies disclosed in the report[11]. - The report indicates no changes in the participation of major shareholders in margin trading activities[11].
科源制药(301281) - 2024 Q3 - 季度财报